CARv3-TEAM-E T Cells in Glioblastoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem glejaka wielopostaciowego (nowy lub powracający)
- •Obecna mutacja EGFRvIII lub amplifikacja EGFR w komórkach nowotworu
- •Wcześniejsze leczenie promieniowaniem
- •Pierwsza wznowa choroby i planowana biopsja lub operacja
- •Co najmniej 2 tygodnie od ostatniej chemioterapii lub immunoterapii
- •Co najmniej 5 czasów połowicznego rozpadu od innych badanych leków
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Massachusetts General Hospital Cancer Center
Boston, United States
Trial contact
William Curry, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.